Lexiscan is a coronary vasodilator drug owned by Astellas. It contains the active ingredient regadenoson and was first approved for market use on April 10, 2008. Astellas holds a total of 3 patents for Lexiscan, out of which one has expired.
The generic version of Lexiscan may become available after February 2, 2027, following the expiration of the patent USRE47301. This patent, titled 'Process for preparing an A2A-adenosine receptor agonist and its polymorphs', is set to expire on the said date.
Lexiscan is primarily used to stimulate coronary vasodilation for imaging the heart. Its active ingredient, regadenoson, contributes to its effectiveness in this role.
Lexiscan has a total of 3 patents, out of which one has already expired. The remaining two are set to expire on February 2, 2027. One of these, USRE47301, is titled 'Process for preparing an A2A-adenosine receptor agonist and its polymorphs'. Once these patents expire, the Lexiscan generic may be released. Below are the details of the patents: